Gillheeney Gary S. 4

What Happened

• Gary S. Gillheeney, President, CEO and Director of Organogenesis (ORGO), received awards on Feb 18, 2026 totaling 1,585,388 shares (three grant/settlement entries) and had 90,398 shares disposed to cover tax liabilities. The withheld shares were recorded at $3.84 each, totaling $347,128. The acquisitions include restricted stock units and performance-related awards; one line is a derivative award (see footnotes).

Key Details

• Transaction date: 2026-02-18; filing date: 2026-02-20 (appears timely).
• Grants/settlements: 890,625 shares (RSUs), 186,968 shares (performance-share settlement), and 507,795 shares recorded as a derivative award — total 1,585,388 shares acquired at $0.00 per share (award/vesting).
• Disposal: 90,398 shares withheld/disposed at $3.84 to satisfy tax withholding, value = $347,128.
• Shares owned after transaction: not specified in the filing excerpt provided.
• Footnotes: F1 = RSUs under 2018 Equity Incentive Plan vesting in equal annual installments over four years beginning Feb 15, 2026; F2 = shares from 2025 performance award settled upon achieving milestones; F3 = option/derivative becomes exercisable in equal annual installments over four years beginning Feb 15, 2026.
• Transaction codes: A = Award/Grant, F = payment of exercise price or tax liability (tax withholding).

Context

• Most activity was award/vesting (acquisitions), which is common compensation-related insider activity; the 90,398-share disposition was a routine tax withholding to cover tax obligations on vested awards, not an open-market sale.
• The derivative/option-related award will vest or become exercisable over multiple years (per F1/F3), so not all awarded shares are freely tradable immediately.